**Introduction**

Mitogen-activated protein kinase (MAPK) likely plays a critical role in the pathogenesis of rheumatoid arthritis (RA), which is a chronic inflammatory disease marked by cytokine production, synovial lining hyperplasia, and joint destruction. Three major MAPK families that differ in their substrate specificity and responses to stress have been identified in vertebrates and have been implicated in RA: c-Jun N-terminal kinase (JNK), extracellular regulating kinase (ERK), and p38 kinase (1). MAPKs phosphorylate selected intracellular proteins, including transcription factors, that subsequently regulate gene expression by transcriptional and posttranscriptional mechanisms (2, 3). MAPKs are, in turn, activated by phosphorylation at conserved threonine and tyrosine residues by upstream dual-specific MAPK kinases (MAPKKs), which themselves are activated by MAPKK kinases (4).

The role of cytokines in the pathogenesis of RA is increasingly appreciated (5), but the signal transduction pathways that determine matrix degradation are only partially understood. Overexpression of matrix metalloproteinases (MMPs), which play a critical role in rheumatoid joint destruction, is of particular interest (6). MMP production might be regulated, in part, by increased activation of c-Jun amino-terminal kinase (JNK) since this MAPK activates key transcription factors involved in MMP gene expression. Several JNK isoforms, encoded by three genes, phosphorylate specific sites (serine 63 and serine 73) on the amino-terminal transactivation domain of c-Jun after exposure to ultraviolet irradiation, growth factors, or cytokines (7, 8). By phosphorylating these sites, the JNKs enhance the transcriptional activity of AP-1, a key regulator of MMP production.

Our previous studies demonstrated that IL-1 is a potent inducer of JNK phosphorylation and collagenase gene expression in RA synoviocytes (9). However, evaluation of this pathway in arthritis has been hampered by the lack of selective compounds to block JNK function in vivo and in vitro. Using a novel selective JNK inhibitor (10), we now report that JNK blockade suppresses MMP and bone destruction in an animal model of arthritis. Furthermore, data from synoviocytes derived from JNK knockout mice confirmed the importance of JNK in metalloproteinase expression.
Methods

Patient selection and cell preparation. Fibroblast-like synoviocytes (FLS) were isolated from RA synovial tissues obtained at joint replacement surgery as described previously (11). The diagnosis of RA conformed to the 1987 revised American College of Rheumatology criteria (12). Briefly, the tissues were minced and incubated with 1 mg/ml collagenase in serum-free DMEM (Life Technologies Inc., Grand Island, New York, USA) for 2 hours at 37°C, filtered through a nylon mesh, extensively washed, and cultured in DMEM supplemented with 10% FCS (endotoxin content less than 0.006 ng/ml; Life Technologies Inc.), penicillin, streptomycin, and L-glutamine in a humidified 5% CO2 atmosphere. After overnight culture, nonadherent cells were removed, and adherent cells were cultured in DMEM plus 10% FCS. At confluence, cells were trypsinized, split at a 1:3 ratio, and recultured in medium. Synoviocytes were used from passages three through nine in these experiments, during which time they were a homogeneous population of FLSs (<1% CD11b, <1% phagocytic, and <1% Fc-gamma RII receptor positive).

Reagents. SP600125 (anthr[1,9-cd]pyrazol-6(2H)-one) (see Figure 1) is a novel JNK inhibitor synthesized by the Department of Chemistry at Signal Research Division of Celgene Inc., San Diego, California, USA. The IC50 for this compound on various kinases and other enzymes are shown in Table 1. These studies were performed on the recombinant enzymes (see below for methods). The chemistry and biochemical analysis will be reported elsewhere (10). SB203580 (p38 inhibitor, IC50: 10 nM) was purchased from Calbiochem-Novabiochem Corp. (San Diego, California, USA) and PD98059 (MEK1/2 inhibitor, IC50: 10 µM) was obtained from New England Biolabs Inc., Beverly, Massachusetts, USA). The following reagents were also used: IL-1β (Boehringer Mannheim Biochemicals Inc., Indianapolis, Indiana, USA), glutathione-S-transferase-c-Jun (GST-c-Jun) and glutathione-S-transferase-activating transcription factor-2 (GST-ATF2) (Signal Pharmaceuticals Inc., San Diego, California, USA), complete protease inhibitor cocktail (Boehringer Mannheim Biochemicals Inc.), protein A-Sepharose 4B-CL (Promega Corp., Madison, Wisconsin, USA).

In vitro kinase assays. In vitro kinase assays were performed in duplicate for 60 minutes at room temperature and contained the following: 50 ng JNK2, 20 mM HEPES, pH 7.6, 10 mM MgCl2, 1.5 mM DTT, 0.5 µCi γ32P-ATP, 50 mM NaCl, 0.03% Triton X-100, 0.1 mM EDTA. JNK2 activity was measured at 2 µM ATP and 2 µM GST-c-Jun with increasing concentrations of SP600125 to determine the IC50. ERK1, IκB kinase (IKK), and p38-2 assays were similar to the JNK assay except for the use of different recombinant enzymes and substrate. The ERK, p38-2 and IKK assays measured the phosphorylation of myelin basic protein, GST-ATF2 and GST-IκB (amino acids 1–54), respectively. Similar analyses were performed using increasing concentrations of SP600125 with the appropriate substrate by Cerep Inc. (Redmond, Washington, USA) to inhibit a panel of recombinant enzymes as shown in Table 1.

JNK1 and JNK2 knockout mouse synoviocytes. Six-week-old JNK1 and JNK2 knockout mice were produced by C57BL/6 backcrossing with SV12a and then backcrossing with C57BL/6 for another five generations to obtain homozygous progeny, and mice homozygous for the targeted gene were analyzed for phenotype (13, 14). Synovial tissue was microdissected from the ankle joints of mice and subsequently minced and incubated with 1 mg/ml collagenase in serum-free DMEM (Life Technologies Inc.) for 2 hours at 37°C, filtered through a nylon mesh, extensively washed, and cultured in DMEM supplemented with 10% FCS (endotoxin content less than 0.006 ng/ml; Life Technologies Inc.), penicillin, streptomycin, and L-glutamine in a humidified 5% CO2 atmosphere. After overnight culture, nonadherent cells were removed and adherent cells were cultivated in DMEM plus 10% FCS. At confluence, cells were trypsinized, split at a 1:3 ratio, and recultured in medium.

In vitro enzyme inhibition studies. The IC50 for SP600125 on JNK was measured using recombinant JNK2 with GST-c-Jun (amino acids 1–79) as a substrate. All reactions were performed in duplicate for 60 minutes at room temperature and contained the following: 50 ng JNK2, 20 mM HEPES, pH 7.6, 10 mM MgCl2, 1.5 mM DTT, 0.5 µCi γ32P-ATP, 50 mM NaCl, 0.03% Triton X-100, 0.1 mM EDTA. JNK2 activity was measured at 2 µM ATP and 2 µM GST-c-Jun with increasing concentrations of SP600125 to determine the IC50.
Table 1

<table>
<thead>
<tr>
<th>Enzyme</th>
<th>IC₅₀ (µM)</th>
<th>Enzyme</th>
<th>IC₅₀ (µM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNK1</td>
<td>0.11</td>
<td>Phospholipase A2</td>
<td>&gt;10</td>
</tr>
<tr>
<td>JNK2</td>
<td>0.11</td>
<td>Adenylate cyclase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>JNK3</td>
<td>0.15</td>
<td>Guanylate cyclase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>ERK2</td>
<td>&gt;30</td>
<td>ATPase (Na/K)</td>
<td>&gt;10</td>
</tr>
<tr>
<td>p38B</td>
<td>&gt;30</td>
<td>Protein kinase C</td>
<td>&gt;10</td>
</tr>
<tr>
<td>IkB kinase-2</td>
<td>&gt;30</td>
<td>HIV-1 protease</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Acetylcholine esterase</td>
<td>&gt;10</td>
<td>Monoamine oxidase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>Cyclooxygenase-2</td>
<td>&gt;10</td>
<td>Tyrosine hydrolase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>S⁺-lipoxigenase</td>
<td>&gt;10</td>
<td>Elastase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>PDE I, III, IV, V</td>
<td>&gt;10</td>
<td>Cathepsin B, G</td>
<td>&gt;10</td>
</tr>
<tr>
<td>PDE IV</td>
<td>7</td>
<td>EGF tyrosine kinase</td>
<td>&gt;10</td>
</tr>
<tr>
<td>iNOS</td>
<td>&gt;10</td>
<td>Cathepsin B, G</td>
<td>&gt;10</td>
</tr>
</tbody>
</table>

Inhibitory activity of SP600125 on various enzymes.

The Journal of Clinical Investigation | July 2001 | Volume 108 | Number 1

75
then resolved on a 4% polyacrylamide gel. The gel was transferred to Whatman paper, dried, and visualized by autoradiography. Controls were performed in each case with mutant oligonucleotides or cold oligonucleotides to compete with labeled sequences.

**Adjuvant arthritis model.** Male Lewis rats (150–200 g) were immunized with complete Freund’s adjuvant on day 0 (16). In this model, arthritis typically begins on day 10 and reaches a plateau from day 16 to 20. Treatment with subcutaneous SP600125 or vehicle (40% polyethylene glycol [PEG] 400 in PBS) was begun on day 8 and was continued daily. Paw swelling was determined by water displacement plethysmography. Roentgenograms were obtained of the right hind paw to assess bone changes using a semiquantitative scoring system: demineralization (0–2+); ankle and mid-foot erosions (0–2+); calcaneal erosion (0–1+); heterotopic bone formation (0–1+), with a maximum possible score of 6. A histologic scoring system was used to evaluate joint inflammation and damage: synovial inflammation (0–4+), cartilage integrity (0–4+), bone erosions (0–4+), marrow infiltration (0–4+), and extra-articular inflammation (0–4+), with a maximum score of 16.

**Statistics.** Data were compared using Student’s t test, and a P value less than 0.05 was considered significant. Data are presented as mean plus or minus SEM.

**Results**

**Effect of MAPK inhibitors on JNK activity in RA FLS.** Initial studies were performed to determine the effect of the MAPK inhibitors on phosphorylation of transcription factors c-Jun and ATF2 using in vitro kinase assays. To compare the activity of the different MAPK and MAPKK inhibitors, RA FLS were incubated with the novel JNK inhibitor SP600125 (see Figure 1 for structure and Table 1 for a profile of activity on various enzymes), the MEK inhibitor PD98059 (which blocks ERK activation), or the p38α/β inhibitor SB203580 for 30 minutes and then stimulated with IL-1. IL-1–stimulated JNK activity measured with a GST-Jun substrate was blocked by 20 µM of SP600125 (Figure 2). It is of interest that 100 µM of PD98059 partially inhibited this activity, but SB203580 was inactive at concentrations that completely blocked p38. Both the JNK inhibitor and the p38α/β inhibitor blocked phosphorylation of GST-ATF2 by the extracts, consistent with the ability of both JNK and p38 to phosphorylate ATF2 (17). No cytotoxicity was observed at the concentrations of SP600125 tested in these assays.

**Effect of MAPK inhibitors on c-Jun phosphorylation in RA FLS.** Having demonstrated that c-Jun phosphorylating activity was inhibited in vitro by SP600125 in RA FLS extracts, we then examined effect of the JNK inhibitor on accumulation of phospho-c-Jun in IL-1–stimulated FLS. Western blot analysis showed that SP600125 and, to a lesser extent PD98059, interfered with JNK activity, while SB203580 had no effect (n = 5) (Figure 3). Additional studies showed that SP600125 blocked c-Jun phosphorylation at both serine 63 and serine 73 (data not shown). While SP600125 is known to inhibit JNK, it was possible that its effect on c-Jun phosphorylation could result from nonspecific inhibition of the upstream kinases JNKK1/MKK4 or JNKK2/MKK7. However, SP600125, PD98059, and SB203580 did not block phosphorylation of JNK in IL-1–stimulated RA FLS (n = 3; data not shown). Therefore, SP600125 functions by directly inhibiting JNK.

**Gene expression of c-jun and c-fos in RA FLS.** MAPKs are thought to be involved in regulation of c-jun and c-fos genes (18). The role of JNK in c-jun and c-fos gene regulation in FLSs was therefore determined using the three MAPK kinase inhibitors. We observed that SP600125 blocked c-jun mRNA accumulation in IL-1–treated cells, while PD98059 primarily blocked c-fos expression (Figure 4). SB203580 had no effect on c-fos or c-jun expression at a concentration that completely inhibits p38 function. Nonspecific toxicity of the JNK inhibitor is not likely since the compound had little effect on either c-fos or GAPDH expression.

**Collagenase and AP-1 expression in RA synoviocytes.** Collagenase (MMP1) plays a critical role in irreversible matrix degradation in RA by cleaving native type II collagen (19). AP-1 is an important IL-1–inducible transcription

---

**Figure 2**

Effect of SP600125 on c-Jun phosphorylating activity. Cultured FLS were stimulated with medium (Med) or 2 ng/ml of IL-1 for 15 minutes in the presence of increasing concentrations of SP600125 (0–20 µM; JNK inhibitor), PD98059 (0–100 µM; MEK/ERK inhibitor), or SB203580 (0–3 µM; p38 inhibitor). The ability of cell lysates to phosphorylate GST-c-Jun or GST-ATF2 was determined. SP600125 inhibited c-Jun and ATF2 phosphorylation in vitro.

**Figure 3**

Effect of MAP kinase inhibitors on phospho-c-Jun (P-c-Jun) levels. Cultured FLSs were stimulated with medium or 2 ng/ml of IL-1 for 15 minutes in the presence of SP600125 (20 µM), PD98059 (100 µM), or SB203580 (3 µM). Phospho-c-Jun and total c-Jun protein levels were determined by Western blot analysis. SP600125 inhibited intracellular c-Jun phosphorylation. The phospho-c-Jun/total Jun protein ratios were medium = 0.18, IL-1 = 1.00, IL-1 + SP600125 = 0.23, IL-1 + PD98059 = 0.73, IL-1 + SB203580 = 1.09.
factor that regulates collagenase gene expression (20). Figure 5a shows that SP600125 suppressed AP-1 binding in IL-1–stimulated FLS. The ERK/MEK inhibitor also had a modest effect, but the p38 inhibitor did not alter AP-1 binding. Because SP600125 inhibits AP-1 activation, its effect on collagenase gene expression was examined. Northern blot analysis indicated that the JNK inhibitor blocked IL-1–induced collagenase expression in RA FLS, although SP600125 (20 µM) did not reduce levels of MMP1 gene expression below baseline (see Figure 5b). This is consistent with the Western blot experiments (Figure 3), indicating that the JNK inhibitor decreased IL-1–induced phospho-c-Jun levels to baseline. SP600125 also inhibited IL-1–induced MMP3 expression in FLS (data not shown). Weak inhibition was observed in cells treated with high concentrations of PD98059, but SB203580 had no effect. Therefore, JNK blockade interferes with transcription factor activation and collagenase gene expression in cultured RA FLS.

**MMP13 and MMP3 expression and regulation in JNK1 and JNK2 knockout synoviocytes.** To prove a direct role of JNK in the regulation of collagenase gene expression, a genetic approach to evaluate the role of JNK in regulation of collagenase gene expression was taken. FLS were isolated from mice with homozygous disruption of the *jnk1* or *jnk2* locus. We examined IL-1–induced MMP3 and MMP13 (collagenase 3) expression instead of MMP1 because mice do not express the MMP1 gene. IL-1 induced significant accumulation of MMP13 and MMP3 mRNA in wild-type FLS. However, MMP13 and MMP3 gene induction was suppressed in FLS isolated from JNK1 and JNK2 knockout mice (*n* = 3) (Figure 6a). Both the JNK1- and JNK2-deficient cells had lower levels of AP-1 binding activity than wild-type cells (Figure 6b).

**Effect of SP600125 on JNK function in vivo.** To determine if SP600125 inhibits JNK function in vivo, adjuvant arthritis was induced in Lewis rats. Beginning on day 8, rats were treated subcutaneously with either 30 mg/kg/d or vehicle. The rats were sacrificed after the onset of arthritis (day 14) 2 hours after drug administration. Ankle joint extracts were subsequently prepared for in vitro kinase assays to determine JNK activity. As seen in Figure 7, the extracts from vehicle-treated rats were able to phospho-
rylate GST-c-Jun substrate, but no kinase activity was detected in the animals that received SP600125. Therefore, systemic administration of SP600125 inhibited JNK function in the joints of rats with adjuvant arthritis.

Effect of JNK inhibition in adjuvant arthritis. To determine the effect of JNK inhibition on matrix remodeling in this disease through their effects on AP-1. Of the three MAPK families, JNK likely plays a central role in this process by virtue of its ability to activate AP-1–mediated transcription (21). AP-1 function is regulated both through changes in the abundance of its Jun and Fos components and post-translational modification by protein phosphorylation (22, 23). The various JNK isoforms, including JNK1, JNK2, and JNK3, phosphorylate two N-terminal serines (amino acids 63 and 73) on c-Jun and subsequently enhance transcriptional activity. In addition to c-Jun, JNK can regulate the expression of other genes through the phosphorylation of ATF2 and Elk1 (24). JNK2 binds c-Jun with greater avidity than the other JNKs and may be the most physiologically relevant isoform, especially in FLS where it is the dominant JNK protein.

Our focus on JNK was stimulated by previous studies demonstrating that JNK phosphorylation is greater in RA than osteoarthritis synoviocytes and correlated with increased MMP expression (9, 25). Furthermore, phospho-JNK has also been observed in intact RA synovium using both immunohistochemistry and Western blot analysis (9, 26).

Previous studies of JNK function in vitro and in vivo have been limited by the lack of a selective inhibitor. Using a novel inhibitor of JNK (SP600125), we evaluat-
ed JNK biology in cultured synoviocytes and in an animal model of arthritis. Initial in vitro experiments showed that SP600125 blocked JNK function in FLS. The inhibitor suppressed IL-1–induced phospho-c-Jun accumulation in synoviocytes as well as c-Jun phosphorylation in cell extracts. SP600125 did not suppress c-Jun phosphorylation below baseline, suggesting that other pathways contribute to basal AP-1 activation. Inhibitors of the other MAPK pathways were also evaluated to determine the relative contributions of each to c-Jun phosphorylation and AP-1 activation. Although JNK played a primary role in c-Jun phosphorylation, ERK also appeared to contribute. However, p38 had no effect on any of the JNK-related functions. SP600125 also inhibited c-jun mRNA accumulation in synoviocytes, whereas ERK was more important in c-fos regulation.

JNK inhibition also decreased the induction of AP-1 DNA-binding activity in synoviocytes, which is primarily dependent on new Jun and Fos protein synthesis in synovial fibroblasts. Of particular interest, SP600125 suppressed the induction of collagenase gene expression, which contains a key AP-1 site in its promoter that is critical for cytokine-induced transcription (18). As with c-Jun phosphorylation, the JNK inhibitor reduced MMP1 to baseline levels. Similar, but less dramatic, results were produced by knockout of the jnk1 or jnk2 loci. The absence of either gene suppressed MMP expression in mouse synoviocytes, although JNK2 appeared to be more important. The relatively greater decrease in the JNK2 knockout mice suggests that this kinase plays a key role. This is consistent with our previous observation that the JNK2 is more abundant than

Figure 8

(a) Effect of SP600125 on adjuvant arthritis in rats. Rats were immunized with complete Freund’s adjuvant on day 0 and treated with vehicle or 30 mg/kg/d of SP600125 subcutaneously beginning on day 8. Significantly less paw swelling was observed in the treated animals. (b) Effect of SP600125 on radiographic damage in adjuvant arthritis. Representative examples of ankle radiographs demonstrate markedly less destruction in the rats treated with SP600125 (top) compared with vehicle (bottom). (c) Effect of SP600125 on synovial collagenase gene expression. Northern blot analysis was performed on joint extracts of vehicle and SP600125-treated rats. Each lane contains the extract of an ankle joint from a control or treated rat (n = 4 for each). Note the lower levels of MMP13 in the SP600125-treated animals (G3PDH-normalized MMP13 mRNA levels for SP600125 = 0.23 ± 0.086 and vehicle = 0.822 ± 0.131, P < 0.01). (d) Effect of SP600125 on synovial AP-1 activation. EMSA analysis was performed on joint extracts of vehicle and SP600125-treated rats with adjuvant arthritis. Positive control is shown on the far left lane of the gel. Note lower levels of AP-1 binding in the SP600125-treated rats (SP600125 = 2.89 ± 0.43 and vehicle = 12.6 ± 2.5, P < 0.01; data presented as arbitrary density units).
either JNK1 or JNK3 in RA synoviocytes (9). SP600125 further decreased MMP expression in the knockout synoviocytes, suggesting that blockade of both JNKs is needed for complete inhibition of MMP production. This is especially an important consideration when assessing murine models of inflammation in JNK knockout mice where only a single locus can be deleted.

The role of individual MAPKs in MMP expression varies with cell type and stimulus. For instance, p38 might play an important role in phorbol ester–induced type IV collagenase production by a squamous cell carcinoma cell line as well as in cytokine-stimulated chondrocytes (27, 28). ERK and JNK have been implicated in the regulation of collagenase gene expression in cultured fibroblasts (29). In contrast to FLS, collagenase and stromelysin gene expression in endothelial cells are dependent on p38 (30). Using both selective inhibitors and genetically modified cells, our data indicate that cytokine-induced MMP1 expression is independent of p38 in synoviocytes, which are the primary source of MMPs in the rheumatoid synovial membrane. While ERK can contribute to collagenase gene expression, JNK is a key MAPK pathway that regulates this process in RA synoviocytes.

After demonstrating a key role of JNK in the regulation of AP-1 and MMP1 expression in vitro, we then evaluated the effect of the compound in vivo. The JNK inhibitor markedly decreased JNK functional activity in arthritic rats treated with the compound. The JNK inhibitor also had a beneficial effect in rat adjuvant arthritis, which is a polyarticular, destructive arthritis that serves as a model for RA (16). SP600125 modestly decreased paw swelling in this model. However, the most striking benefit was on joint destruction. Radiographic evaluation of animals treated with the JNK inhibitor showed significantly less joint damage and remodeling than vehicle-treated controls. Hence, JNK activation is a primary mediator of joint destruction in arthritis.

The mechanism of joint protection in adjuvant arthritis was investigated by determining MMP and AP-1 activation in rats treated with SP600125. As with cultured synoviocytes, the JNK inhibitor suppressed synovial MMP13 gene expression. It is therefore likely that JNK blockade interfered with a cascade of events, beginning with c-Jun phosphorylation and including c-Jun gene expression, AP-1 binding, and MMP1 gene transcription. These data indicate that the JNK pathway lies at a critical convergent point in the regulation of extracellular matrix regulation in arthritis. Alternatively, JNK blockade could potentially alter the immune responses since these kinases play a role in Th1/Th2 balance and T cell activation (13, 31, 32). However, treatment with SP600125 was delayed in order to minimize its effect on the primary T cell responses. Anti-inflammatory and matrix protection actions of therapeutic agents can be readily assessed with delayed treatment (16).

Based on the modest effects on paw swelling, the inflammatory components of arthritis appear to be less dependent on AP-1. This differs somewhat from NF-κB inhibitors, which have tended to demonstrate more prominent anti-inflammatory effects (33–35). We have also observed that suppression of NF-κB activation in the joints of rats with adjuvant arthritis leads to decreased joint inflammation but no change in bone destruction (36). These data suggest that AP-1 and NF-κB might complement each other by primarily regulating destruction or inflammation, respectively. These two aspects of RA are not always linked, and different mechanisms appear to regulate their progression in human RA as well as various animal models (1). Hence, JNK inhibition is a potential therapeutic approach for prevention of matrix destruction. In combination with approaches that suppress other pathways such as NF-κB, both inflammation and joint damage could suppressed in RA.

Acknowledgments

These studies were supported by grants from the Arthritis Foundation and from the Signal Research Division of Celgene Inc.


